VCMMAE, also known as mc-vc-PAB-MMAE, is a specialized drug-linker conjugate used in the development of antibody-drug conjugates (ADCs) to deliver potent cytotoxic payloads to targeted tumor cells. This… Read more
VCMMAE, also known as mc-vc-PAB-MMAE, is a specialized drug-linker conjugate used in the development of antibody-drug conjugates (ADCs) to deliver potent cytotoxic payloads to targeted tumor cells. This molecule integrates the antimitotic agent monomethyl auristatin E (MMAE) with a lysosomally cleavable valine-citrulline (vc) peptide linker and a spacer. Once the ADC is internalized by cells, enzymatic cleavage releases the active MMAE, which inhibits tubulin polymerization and induces apoptosis. Given the complexity of these conjugates, pharmaceutical laboratories rely on high-quality reference standards, including impurities, metabolites, and stable isotope labelled compounds, to support rigorous analytical testing. These materials are essential for accurate impurity profiling, method validation, and ensuring the consistent quality of the drug-linker system throughout the pharmaceutical development and manufacturing process.